Cargando…

Comment on: Incidence of blindness in a population of rheumatic patients treated with hydroxychloroquine

Detalles Bibliográficos
Autores principales:	Pareek, Anil, Mehta, Ravi Tejraj, Dharmadhikari, Shruti, Naidu, Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821282/ https://www.ncbi.nlm.nih.gov/pubmed/31687661 http://dx.doi.org/10.1093/rap/rkz041

Ejemplares similares

Compelling therapy of LVH: straight (and not-so-straight) inferences from evidence
por: Mehta, Ravi Tejraj, et al.
Publicado: (2019)

Comment on: incidence of blindness in a population of rheumatic patients treated with hydroxychloroquine: reply
por: Singh, Dilpreet K, et al.
Publicado: (2019)

Hydroxychloroquine and QT prolongation: reassuring data in approved indications
por: Pareek, Anil, et al.
Publicado: (2020)

Hydroxychloroquine for prophylaxis in COVID-19: Need to revisit dosing regimen
por: Pareek, Anil, et al.
Publicado: (2020)

Incidence of blindness in a population of rheumatic patients treated with hydroxychloroquine
por: Singh, Dilpreet K, et al.
Publicado: (2019)

Chlorthalidone, not hydrochlorothiazide, is the right diuretic for comparison
por: Mehta, Ravi Tejraj, et al.
Publicado: (2018)

REVEAL Study: Reveals the Limitations of Cholesteryl Ester Transfer Protein Inhibition
por: Pareek, Anil, et al.
Publicado: (2018)

DAPA-HF study: Are the benefits uniform across non-diabetic subgroups
por: Pareek, Anil, et al.
Publicado: (2020)

Hydroxychloroquine and QT Prolongation in Older Patients with Rheumatic Diseases: Who is afraid of the Boogeyman? We are not!
por: Castagna, Alberto, et al.
Publicado: (2020)

Impact of hydroxychloroquine used as DMARD on SARS-CoV-2 tests and infection evolution in a population of 871 patients with inflammatory rheumatic and musculoskeletal diseases
por: Trefond, Ludovic, et al.
Publicado: (2021)

Can we use hydroxychloroquine to treat COVID-19 now?
por: Chen, Jun, et al.
Publicado: (2021)

Comment to Sands et al. — No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19
por: Hoang, Van Thuan
Publicado: (2021)

Interamerican Society of Cardiology (IASC) position statement: Chlorthalidone vs. thiazide-type diuretics()
por: Pareek, Anil, et al.
Publicado: (2020)

First evaluation of hydroxychloroquine recommendations in treating SARS-CoV-2
por: Roussel, Y., et al.
Publicado: (2020)

Possible synergistic effects of hydroxychloroquine and steroids in COVID-19, time for a nuanced approach. Comment on Arshad et al.
por: Wiseman, David M.
Publicado: (2020)

Comment on: BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs
por: Pakozdi, Angela, et al.
Publicado: (2017)

Ophthalmologic implications to consider when using hydroxychloroquine to treat COVID-19 and induced arthritis
por: Zeppieri, Marco
Publicado: (2023)

Response to comments: Nebulised fentanyl for post-operative pain relief, a prospective double-blind controlled randomised clinical trial
por: Singh, Anil P, et al.
Publicado: (2014)

A comment on Incidence of occupational exposures in a tertiary health care center
por: Raina, Sunil Kumar
Publicado: (2014)

Fixed Drug Eruption to Hydroxychloroquine
por: Swarnkar, Bhavya, et al.
Publicado: (2021)

Update on hydroxychloroquine use in pregnancy
por: Nori, Wassan, et al.
Publicado: (2023)

Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs
por: Yu, Bo, et al.
Publicado: (2020)

Response to the comments on impact on bronchial asthma in Indian population
por: Ramasamy, Anandha K, et al.
Publicado: (2015)

A Ringed Enigma: A Case of Annular Elastolytic Giant Cell Granuloma Successfully Treated with Hydroxychloroquine
por: Kansara, Kajal G., et al.
Publicado: (2023)

Hydroxychloroquine Reduces Proteinuria in Indian Patients With IgA Nephropathy
por: Bagchi, Soumita, et al.
Publicado: (2022)

Thrombotic microangiopathy: COVID-19 or hydroxychloroquine?
por: Hasbal, Nuri Baris
Publicado: (2020)

Hydroxychloroquine-Associated Thrombotic Thrombocytopenic Purpura
por: Arıkan, Fatma, et al.
Publicado: (2020)

Hydroxychloroquine + azithromycin treatment in elderly patients
por: Gautret, Philippe, et al.
Publicado: (2021)

Hydroxychloroquine, TTP, COVID-19, and SLE
por: Sookaromdee, Pathum, et al.
Publicado: (2021)

Hydroxychloroquine: is there a role in long COVID?
por: Wang, Samuel S. Y., et al.
Publicado: (2023)

Hydroxychloroquine for the management of chronic chikungunya arthritis
por: Nogueira, Igor Albuquerque, et al.
Publicado: (2023)

Comment on: Prevention of Renal Damage by Treating Hyperuricemia
por: Nasri, Hamid, et al.
Publicado: (2015)

Hydroxychloroquine in rheumatic autoimmune disorders and beyond
por: Nirk, Eliise Laura, et al.
Publicado: (2020)

Comment on ‘cancer incidence in the United Kingdom: projections to the year 2030'
por: Oliver, S E, et al.
Publicado: (2013)

Comments on “An unusual cause of bronchial obstruction”
por: Mehta, Asmita
Publicado: (2012)

Hydroxychloroquine in a COVID-19 patient on chronic Pregabalin therapy- Is it safe?
por: Chilkoti, Geetanjali Tolia, et al.
Publicado: (2022)

Comment on: a novel transition clinic structure for adolescent and young adult patients with childhood onset rheumatic disease improves transition outcomes
por: Radić, Mislav
Publicado: (2022)

An antiarrhythmic approach to hydroxychloroquine-induced QT prolongation
por: Yetkin, E., et al.
Publicado: (2020)

Antimalarials (chloroquine and hydroxychloroquine) in the COVID-19 pandemic()
por: Jáuregui, Edwin
Publicado: (2021)

Hydroxychloroquine (HCQ): real treatment or false hope?
por: El Bakkouri, Karim
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_39mgknihefibdstuokasb91n6v